Prague

• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stag … Ended
  2023-507243-11-02 4 2025-01-05 Cardiogenic Shock
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118 … Ended
  2024-514981-37-00 4 2024-12-05 Rheumatoid Arthritis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S. … Ended
  2024-514678-35-00 2 2024-11-15 Bioequivalence study in healthy volunteers under fasting conditions
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• An open label, randomized, crossover, two-period, two-sequence, multiple dose study to assess the relative bioavailability of Rotigotine 4.5 … Ended
  2024-515841-41-00 2 2024-11-04 Not applicable (submitted trial is a bioavailability study in healthy
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Val … Ended
  2024-516184-87-00 2 2024-10-18 not applicable (submitted trial is a bioavailability study in healthy
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 5 2024-10-17 Thyroid Eye Disease (TED)
• An open label, randomized, crossover, two-period, two-sequence, single dose study to assess the relative bioavailability of Rotigotine 4.5 m … Ended
  2024-515840-21-00 2 2024-09-30 Not applicable (submitted trial is a bioavailability study in healthy
• A phase 2b dose finding study of RMC-035 in participants undergoing open-chest cardiac surgery Ended
  2024-510658-28-00 4 2024-09-24 Loss of renal function following cardiac surgery
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata
• Ibuprofen 200 mg bioequivalence study Ended
  2024-516161-36-00 2 2024-09-13 not applicable (submitted trial is BE)
• A Randomized, Single-dose, Crossover, Two-period, Pilot Comparative Bioavailability Study of Alendronate 70 mg effervescent vs. Fosamax 70 m … Ended
  2024-513615-26-00 2 2024-09-12 not applicable (submitted trial is a comparative bioavailability study
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A study to learn about the blood levels of aflibercept when high-dose aflibercept is injected in both eyes of participants with diabetic mac … Ended
  2024-511665-11-00 6 2024-08-29 Neovascular age-related macular degeneration (nAMD)
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease
• A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended
  2023-507942-10-00 4 2024-07-31 Major depressive disorder

Showing 673–696 of 847 trials